Opportunity Information: Apply for PA 17 280
The funding opportunity titled "In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R01)" (Funding Opportunity Number PA 17 280) is a discretionary National Institutes of Health (NIH) research grant announcement focused on hepatitis B virus (HBV) and human immunodeficiency virus (HIV) co-infection. Its central goal is to push the field forward by improving the experimental tools researchers rely on to study how these two viruses interact in the same host and, importantly, to speed up the pipeline for discovering and developing better therapies for people living with both infections.
A major emphasis of the FOA is the creation and refinement of novel laboratory models, specifically new in vitro systems and small animal models that can more accurately reproduce HBV/HIV co-infection. In practical terms, this means supporting projects that build more realistic cell culture platforms (for example, improved hepatocyte-based systems, organoid-like approaches, co-culture methods, or other engineered systems that capture key features of liver infection and immune interaction) and small animal models that can simultaneously represent relevant aspects of HBV infection, HIV infection, and their overlap. The reason this matters is that co-infection is biologically complex, and existing models often fail to mimic the combined virology and immune effects seen in people. Better models allow researchers to test candidate drugs and combinations more reliably, understand safety and efficacy signals earlier, and reduce uncertainty before moving into clinical development.
The FOA also aims to deepen scientific understanding of the immunopathogenic interactions between HBV and HIV. This includes studying how HIV-driven immune dysfunction influences HBV persistence and liver disease progression, how HBV-related liver inflammation and immune activity may affect HIV outcomes, and how co-infection alters immune responses in ways that are not predictable from studying each virus alone. Projects aligned with this goal might examine mechanisms of immune activation, immune exhaustion, cytokine signaling, liver-resident immune cell behavior, viral replication dynamics under co-infection conditions, and other pathways that contribute to liver injury, viral persistence, and differential responses to therapy. The overall intent is not just to build models as tools, but to use those tools to answer mechanistic questions that directly inform therapeutic strategy and drug development decisions.
This is an NIH R01 grant mechanism, meaning it supports investigator-initiated research projects that are typically hypothesis-driven and substantial in scope. The Funding Instrument Type is listed as a grant, and the Funding Activity Category is Education and Health. Multiple CFDA numbers are associated with the announcement (93.273, 93.393, 93.394, 93.395, 93.396, 93.399, 93.855, 93.856), reflecting NIH program and institute alignments that can support research across infectious diseases, immunology, and related biomedical areas.
Eligibility is broad and includes a wide range of domestic and international applicant organizations. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and other entities. The FOA explicitly calls out additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); eligible federal agencies; faith-based or community-based organizations; regional organizations; non-domestic (non-U.S.) entities and foreign organizations; Indian/Native American tribal governments other than federally recognized; and U.S. territories or possessions. This wide eligibility reflects the global and cross-sector relevance of HBV/HIV co-infection research and encourages participation from institutions serving populations disproportionately affected by these diseases.
Key administrative details provided include an original closing date of 2019-01-07 and a creation date of 2017-05-12. The award ceiling and expected number of awards are not specified in the provided data, which often means budgets and award counts may depend on NIH institute priorities, available appropriations, and the scientific merit and fit of applications received.
In summary, this FOA is designed to address a bottleneck in HBV/HIV co-infection research by funding the development of more faithful in vitro and small animal models and leveraging those models to uncover the immune and disease mechanisms that drive co-infection outcomes. The long-term payoff NIH is aiming for is straightforward: stronger experimental platforms that make preclinical testing more predictive, shorten timelines for therapeutic discovery and development, and ultimately improve prevention and treatment strategies for people living with HBV/HIV co-infection.Apply for PA 17 280
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273, 93.393, 93.394, 93.395, 93.396, 93.399, 93.855, 93.856.
- This funding opportunity was created on 2017-05-12.
- Applicants must submit their applications by 2019-01-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs): In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R01)
What is the title of this funding opportunity?
The funding opportunity is titled "In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R01)".
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number provided is PA 17 280.
Which agency is offering this grant opportunity?
This is a discretionary research grant announcement from the National Institutes of Health (NIH).
What type of grant mechanism is being used?
This opportunity uses the NIH R01 mechanism, which supports investigator-initiated research projects that are typically hypothesis-driven and substantial in scope.
What is the main purpose of this FOA?
The central goal is to advance HBV/HIV co-infection research by improving experimental tools used to study how hepatitis B virus (HBV) and human immunodeficiency virus (HIV) interact in the same host, and to help accelerate discovery and development of better therapies for people living with both infections.
What research areas does the FOA emphasize?
The FOA emphasizes two closely connected areas:
- Development and refinement of novel laboratory models for HBV/HIV co-infection (new in vitro systems and small animal models).
- Mechanistic studies of immunopathogenic interactions between HBV and HIV, using improved models to generate insights that inform therapeutic strategy and drug development.
What kinds of in vitro models are encouraged under this FOA?
The FOA highlights support for more realistic cell-culture platforms that better reproduce HBV/HIV co-infection biology. Examples mentioned include improved hepatocyte-based systems, organoid-like approaches, co-culture methods, and other engineered systems designed to capture key features of liver infection and immune interaction.
What kinds of animal models are encouraged under this FOA?
The FOA places major emphasis on small animal models that can simultaneously represent relevant aspects of HBV infection, HIV infection, and their overlap, with the goal of more faithfully reproducing the combined virology and immune effects observed in people.
Why does NIH consider new co-infection models a priority?
HBV/HIV co-infection is biologically complex, and existing models often do not mimic the combined viral and immune effects seen in humans. More accurate models are intended to make preclinical testing more predictive, help identify safety and efficacy signals earlier, and reduce uncertainty before moving candidate therapies into clinical development.
Does this FOA focus only on creating models, or also on using them for discovery?
It focuses on both. NIH is aiming not only to develop better models as research tools, but also to use those tools to answer mechanistic questions that directly inform therapeutic strategy and drug development decisions.
What kinds of mechanistic questions does the FOA aim to support?
The FOA aims to deepen understanding of the immunopathogenic interactions between HBV and HIV, such as:
- How HIV-driven immune dysfunction influences HBV persistence and liver disease progression
- How HBV-related liver inflammation and immune activity may affect HIV outcomes
- How co-infection alters immune responses in ways that are not predictable from studying each virus alone
What specific biological processes or pathways are mentioned as relevant?
The FOA mentions potential focus areas including immune activation, immune exhaustion, cytokine signaling, liver-resident immune cell behavior, and viral replication dynamics under co-infection conditions, among other pathways contributing to liver injury, viral persistence, and differential responses to therapy.
What is the expected long-term impact NIH is aiming for?
The intended long-term payoff is stronger experimental platforms that make preclinical testing more predictive, shorten timelines for therapeutic discovery and development, and ultimately improve prevention and treatment strategies for people living with HBV/HIV co-infection.
What is the funding instrument type?
The funding instrument type is listed as a grant.
What is the funding activity category?
The funding activity category is listed as Education and Health.
Which CFDA numbers are associated with this FOA?
The FOA lists multiple CFDA numbers: 93.273, 93.393, 93.394, 93.395, 93.396, 93.399, 93.855, 93.856. These reflect NIH program and institute alignments that can support research spanning infectious diseases, immunology, and related biomedical areas.
Who is eligible to apply?
Eligibility is broad and includes a wide range of domestic and international applicant organizations. Eligible applicants include:
- State, county, and local governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments
- Native American tribal organizations that are not federally recognized
- Public housing authorities and Indian housing authorities
- Nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education)
- For-profit organizations (other than small businesses)
- Small businesses
- Other entities
Are international (non-U.S.) organizations eligible?
Yes. The FOA explicitly includes non-domestic (non-U.S.) entities and foreign organizations as eligible applicants.
Does the FOA encourage applications from institutions serving disproportionately affected populations?
Yes. The FOA explicitly calls out additional eligible groups, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, and TCCUs, reflecting an intent to encourage broad participation, including from institutions serving communities disproportionately affected by HBV and HIV.
Are faith-based or community-based organizations eligible to apply?
Yes. The FOA explicitly includes faith-based or community-based organizations among eligible applicants.
Are U.S. territories or possessions included in eligibility?
Yes. The FOA explicitly includes U.S. territories or possessions among eligible applicants.
Are federal agencies eligible to apply?
Yes. The FOA explicitly lists eligible federal agencies among the eligible applicant types.
What is the original closing date listed for this opportunity?
The original closing date provided is 2019-01-07.
When was this funding opportunity created?
The creation date provided is 2017-05-12.
Is an award ceiling specified?
No. The award ceiling is not specified in the provided information.
Is the expected number of awards specified?
No. The expected number of awards is not specified in the provided information.
What does it mean if the award ceiling and number of awards are not specified?
Based on the provided description, the absence of specified limits often indicates that budgets and award counts may depend on NIH institute priorities, available appropriations, and the scientific merit and fit of the applications received.
What problem or bottleneck is this FOA trying to address?
This FOA is designed to address a major bottleneck in HBV/HIV co-infection research: the lack of sufficiently faithful in vitro and small animal models that can capture the combined biology of both viruses and the resulting immune and disease interactions.
How does this FOA connect model development to therapy development?
The FOA links improved models to therapeutic progress by aiming to make preclinical testing more reliable and predictive. Better models can support more confident testing of candidate drugs and drug combinations, earlier identification of safety/efficacy signals, and clearer mechanistic evidence to guide drug development decisions.
Browse more opportunities from the same category: Education, Health
Next opportunity: Human Tumor Atlas Network: Data Coordinating Center (U24)
Previous opportunity: NCATS Pilot Program for Collaborative Drug Discovery Research using Bioprinted Skin Tissue (U18)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 17 280
Applicants also applied for:
Applicants who have applied for this opportunity (PA 17 280) also looked into and applied for these:
| Funding Opportunity |
|---|
| HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research (R01) Apply for PA 17 279 Funding Number: PA 17 279 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Wearable to Track Recovery and Relapse Factors for People w/ Addiction(R43/R44) Apply for RFA DA 18 010 Funding Number: RFA DA 18 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Exploring Novel RNA Modifications in HIV/AIDS and Substance Use Disorders (R01) Apply for RFA DA 18 008 Funding Number: RFA DA 18 008 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Exploring Novel RNA Modifications in HIV/AIDS and Substance Use Disorders (R21) Apply for RFA DA 18 009 Funding Number: RFA DA 18 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R21) Apply for PA 17 281 Funding Number: PA 17 281 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research (R21) Apply for PA 17 278 Funding Number: PA 17 278 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Leveraging Population-based Cancer Registry Data to Study Health Disparities (R01) Apply for PA 17 289 Funding Number: PA 17 289 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Leveraging Population-based Cancer Registry Data to Study Health Disparities (R21) Apply for PA 17 288 Funding Number: PA 17 288 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Addressing Suicide Research Gaps: Aggregating and Mining Existing Data Sets for Secondary Analyses (R01) Apply for RFA MH 18 400 Funding Number: RFA MH 18 400 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Silencing of HIV-1 Proviruses (R61/R33) Apply for RFA AI 17 013 Funding Number: RFA AI 17 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| U.S. Tobacco Control Policies to Reduce Health Disparities (R01) Apply for PAR 17 217 Funding Number: PAR 17 217 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| U.S. Tobacco Control Policies to Reduce Health Disparities (R21) Apply for PAR 17 218 Funding Number: PAR 17 218 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| HIV/AIDS and the Tumor Niche (R01) Apply for RFA CA 17 030 Funding Number: RFA CA 17 030 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Addressing Suicide Research Gaps: Understanding Mortality Outcomes (R01) Apply for RFA MH 18 410 Funding Number: RFA MH 18 410 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Imaging the Persistent HIV Reservoir (R01) Apply for PA 17 305 Funding Number: PA 17 305 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HIV/HCV Co-Infections in Substance Abusers (R01) Apply for PAS 17 311 Funding Number: PAS 17 311 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Competition Cohort Studies of HIV/AIDS and Substance Abuse (U01) Apply for RFA DA 18 011 Funding Number: RFA DA 18 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Integration of Individual Residential Histories into Cancer Research (R21) Apply for PA 17 295 Funding Number: PA 17 295 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Integration of Individual Residential Histories into Cancer Research (R01) Apply for PA 17 298 Funding Number: PA 17 298 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Multidisciplinary Studies of HIV/AIDS and Aging (R21) Apply for PAR 17 320 Funding Number: PAR 17 320 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 17 280", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.